Recombinant Interferon-Beta-1 alpha Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Kim, Yong Soo | - |
dc.contributor.author | Kim, Ja Kyung | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Chon, Chae Yoon | - |
dc.contributor.author | Moon, Young Myoung | - |
dc.date.accessioned | 2023-03-09T00:06:54Z | - |
dc.date.available | 2023-03-09T00:06:54Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/65282 | - |
dc.description.abstract | Background/Aims: Interferon beta (IFN-beta) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-beta (IFN-beta-1a) plus oral ribavirin versus interferon alpha (IFN-alpha) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). Methods: Twenty treatment-naive patients were randomized into two equal-sized treatment groups. Both IFN-beta-1a (44 mu g) and IFN-alpha (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. Results: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-beta-1a group and IFN-alpha groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-beta-1a group than in the IFN-alpha group, and there were more HCV genotype 1 patients in the IFN-beta-1a group (eight versus seven). The IFN-beta-1a group was associated with similar adverse events in terms of frequency and severity. Conclusions: The SVR rate and safety profile were similar for the combination of IFN-beta-1a and ribavirin and that of IFN-alpha and ribavirin. (Gut and Liver 2009;3:20-25) | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.title | Recombinant Interferon-Beta-1 alpha Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.5009/gnl.2009.3.1.20 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.3, no.1, pp 20 - 25 | - |
dc.identifier.kciid | ART001570103 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000264439300003 | - |
dc.identifier.scopusid | 2-s2.0-67249144306 | - |
dc.citation.endPage | 25 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 20 | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 3 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.subject.keywordAuthor | Interferons | - |
dc.subject.keywordAuthor | Prospective studies | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-C | - |
dc.subject.keywordPlus | INTERFERON-BETA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PHARMACODYNAMICS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kciCandi | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.